NCT00736450: Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma |
|
|
| Terminated | 1 | 37 | US | oblimersen sodium, augmerosen, G3139, G3139 bcl-2 antisense oligodeoxynucleotide, Genasense, rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, doxorubicin hydrochloride, ADM, ADR, Adria, Adriamycin PFS, Adriamycin RDF, vincristine sulfate, leurocristine sulfate, VCR, Vincasar PFS, prednisone, DeCortin, Deltra, biopsy, biopsies, microarray analysis, gene expression profiling, immunohistochemistry staining method, immunohistochemistry, gene expression analysis, cytogenetic analysis | University of Nebraska, National Cancer Institute (NCI), Genta Incorporated | Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma | 10/12 | 10/12 | | |
